Contemporary management of chronic stable angina
1Department of Cardiology, St Bartholomew's Hospital, West Smithfield, London, England. adstaniforth@beeb.net
Insights
Chronic stable angina management is complex. Beta-blockers may improve survival, while angioplasty offers symptom relief but not mortality benefits. Surgery benefits select high-risk patients.
Area of Science:
- Cardiology
- Clinical Medicine
Background:
- Chronic stable angina prognosis is often underestimated.
- Optimal treatment strategies and evidence for anti-ischemic agents are not well-established.
- Existing evidence for anti-ischemic therapy is derived from acute coronary syndromes or surrogate endpoints.
Purpose of the Study:
- To review the evidence for various treatment strategies in chronic stable angina.
- To clarify the mortality benefits and symptom relief offered by different interventions.
- To discuss alternative therapies for refractory angina.
Main Methods:
- Review of existing literature and clinical trial data.
- Analysis of evidence from studies on acute coronary syndromes and chronic angina with surrogate endpoints.
- Evaluation of mortality data and symptom relief outcomes for medical, interventional, and surgical treatments.
Main Results:
- Beta-blockers are suggested to offer a mortality benefit in chronic stable angina.
- Lipid-lowering therapy and antiplatelet agents have proven mortality benefits.
- Angioplasty provides symptom relief but no mortality benefit; coronary bypass surgery offers a mortality advantage in specific high-risk patients.
Conclusions:
- Treatment decisions for chronic stable angina require careful consideration of individual patient factors and risk stratification.
- While medical therapy, particularly beta-blockers, shows potential mortality benefits, revascularization strategies like angioplasty and bypass surgery have distinct roles in symptom management and survival.
- Refractory angina may benefit from alternative therapies such as cardiac transplantation or spinal cord stimulation.
Abstract:
Chronic stable angina is a common condition with a prognosis that is less benign than is generally appreciated. The optimal treatment strategy of this disorder is unclear, and few anti-ischaemic agents have been rigorously tested in prospectively randomised mortality studies. The evidence base for the anti-ischaemic therapy of chronic angina draws upon data 'borrowed' from studies in acute coronary syndromes, and from studies in chronic angina using surrogate endpoints such as ambulatory silent ischaemia. Such evidence leads us to believe that anti-ischaemic therapy with beta-blockers offers a mortality benefit in chronic angina. In contrast, the mortality benefit of lipid lowering therapy and antiplatelet agents is well proven. Angioplasty offers no mortality benefit in the treatment of chronic angina, although it is more effective than medical therapy alone for the relief of symptoms. In a few patients with high order proximal coronary disease, coronary bypass surgery offers a distinct mortality advantage compared with medical treatment alone. Most patients, however, do not warrant such an approach, and only require surgery for when they remain symptomatic despite adequate medical therapy. Alternative strategies such as cardiac transplantation, transmyocardial laser revascularisation and spinal cord stimulation are now accepted in a subgroup of patients for the treatment of chronic angina refractory to standard therapy.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Acute Coronary Syndrome V: Nursing Management
01:26Angina IV: Management
01:20Angina V: Nursing Management
01:26Atherosclerosis III: Management